SCHEMBL4749775

SCHEMBL4749775

Cc1n[nH]c(O)c1-c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 3/20 0.66
CHEK1 O14757 2/20 0.66
KMT2A Q03164 1/20 0.47
ALOX5 P09917 1/20 0.43
BRD4 O60885 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BRD2 P25440 1/20 0.41
RPS6KA3 P51812 2/20 0.41
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDO2 P48775 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
COMT P21964 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873114 0.79 AKT2 (1.00) AKT2CHEK1KMT2ABRD4L3MBTL1
SCHEMBL5865715 0.78 AKT2 (0.68) AKT2CHEK1KMT2ABRD4L3MBTL1
SCHEMBL15713879 0.78 MEN1 (0.49) AKT2CHEK1KMT2ARPS6KA3MAPK1
SCHEMBL11116234 0.76 AKT2 (0.66) AKT2CHEK1KMT2ABRD4L3MBTL1
SCHEMBL6209997 0.76 AKT2 (0.66) AKT2CHEK1KMT2ABRD4L3MBTL1
SCHEMBL27260360 0.76 AKT2 (0.66) AKT2CHEK1KMT2ABRD4L3MBTL1
SCHEMBL1057636 0.76 AKT2 (0.66) AKT2CHEK1KMT2ABRD4L3MBTL1
SCHEMBL27518675 0.76 AKT2 (0.59) AKT2CHEK1KMT2AMAPK1NPSR1
SCHEMBL8081940 0.75 ALDH1A1 (0.50) KMT2ANPSR1TP53MAPTCNR1
SCHEMBL17637927 0.74 AKT2 (0.63) AKT2CHEK1KMT2AL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682938-B2 Pyrazolone derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
EP-3148972-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS Cardioxyl Pharmaceuticals Inc. (US) 2017-04-05 EP disclosed
WO-2015183839-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-12-03 WO disclosed
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2015-12-03 US disclosed
WO-2008121861-A2 PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS TNNI3, PFKP, NOX5 AKT2 1402/4885CHEK1 2281/4885KMT2A 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.